Cannapharmarx Free Cash Flow (FCF) History (CPMD)
Cannapharmarx reported −$794,621 in free cash flow for fiscal 2025, an increase of $902,611 from the previous fiscal year, with a free cash flow margin of −58.34%.
View full Cannapharmarx company overviewCannapharmarx free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | −$794,621 | $902,611 | — | −58.34% |
| 2024 | 2024-12-31 | −$1.7M | −$132,870 | — | −206.94% |
| 2022 | 2022-12-31 | −$1.6M | $856,557 | — | — |
| 2021 | 2021-12-31 | −$2.4M | −$1.9M | — | — |
| 2020 | 2020-12-31 | −$563,573 | $3.2M | — | — |
| 2019 | 2019-12-31 | −$3.8M | −$2.9M | — | — |
| 2018 | 2018-12-31 | −$941,136 | −$918,756 | — | — |
| 2016 | 2016-12-31 | −$22,380 | $2.5M | — | — |
| 2015 | 2015-12-31 | −$2.6M | −$909,010 | — | — |
| 2014 | 2014-12-31 | −$1.6M | — | — | — |
Cannapharmarx quarterly free cash flow
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q3 2024 | 2024-09-30 | −$540,897 | $71,734 | — | −173.27% |
| Q1 2024 | 2024-03-31 | −$548,829 | $551,753 | — | −2124.03% |
| Q3 2023 | 2023-09-30 | $45,889 | −$236,255 | −83.74% | — |
| Q2 2023 | 2023-06-30 | −$555,977 | −$201,815 | — | — |
| Q1 2023 | 2023-03-31 | −$612,631 | −$220,869 | — | — |
| Q4 2022 | 2022-12-31 | −$1.1M | −$773,262 | — | — |
| Q3 2022 | 2022-09-30 | $282,144 | $1.3M | — | — |
| Q2 2022 | 2022-06-30 | −$354,162 | −$97,617 | — | — |
| Q1 2022 | 2022-03-31 | −$391,762 | $413,803 | — | — |
| Q4 2021 | 2021-12-31 | −$327,320 | −$596,069 | — | — |
| Q3 2021 | 2021-09-30 | −$1.0M | −$872,872 | — | — |
| Q2 2021 | 2021-06-30 | −$256,545 | $51,132 | — | — |
| Q1 2021 | 2021-03-31 | −$805,565 | −$439,885 | — | — |
| Q4 2020 | 2020-12-31 | $268,749 | $268,750 | — | — |
| Q3 2020 | 2020-09-30 | −$158,965 | −$158,965 | — | — |
| Q2 2020 | 2020-06-30 | −$307,677 | −$302,868 | — | — |
| Q1 2020 | 2020-03-31 | −$365,680 | −$348,110 | — | — |
| Q4 2016 | 2016-12-31 | −$1 | $340,757 | — | — |
| Q3 2016 | 2016-09-30 | $0 | $737,492 | — | — |
| Q2 2016 | 2016-06-30 | −$4,809 | $818,041 | — | — |
| Q1 2016 | 2016-03-31 | −$17,570 | $632,167 | — | — |
| Q4 2015 | 2015-12-31 | −$340,758 | $150,981 | — | — |
| Q3 2015 | 2015-09-30 | −$737,492 | — | — | — |
| Q2 2015 | 2015-06-30 | −$822,850 | — | — | — |
| Q1 2015 | 2015-03-31 | −$649,737 | — | — | — |
| Q3 2014 | 2014-09-30 | −$491,739 | — | — | — |
Cannapharmarx free cash flow growth trends
Over the last five reported fiscal years, free cash flow grew from −$3.8M to −$794,621, a net increase of $3.0M. Cannapharmarx's latest reported quarter, Q3 2024, generated −$540,897 in free cash flow, an increase of $71,734 year over year.
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Cannapharmarx filings at SEC.gov ↗